Cytokine-based therapy and biochemotherapy for advanced melanoma

Clinical Cancer Research

Volumn 12, Issue 7 II, 2006, Pages

  Atkins, Michael B ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CISPLATIN; CYTOKINE; DACARBAZINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 18 BINDING PROTEIN; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; TAMOXIFEN; VINBLASTINE;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CELL POPULATION; CLINICAL TRIAL; DOSE RESPONSE; DRUG MECHANISM; HUMAN; MELANOMA; MICROENVIRONMENT; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER VACCINES; COMBINED MODALITY THERAPY; CYTOKINES; HUMANS; IMMUNOTHERAPY; MELANOMA; SKIN NEOPLASMS; T-LYMPHOCYTES;

EID: 33646252963     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2503     Document Type: Review

References (28)

1. Atkins M, Lotze M, Dutcher J. High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17:2105.
2. Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 2000;6:S11-4.
3. Balch CAM, Sober AJ. Cutaneous Melanoma. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer principles and practice of oncology. 7th ed. Philadelphia: Lippincott Williams & Wilkins Philadelphia; 2004. p. 1754-809.
4. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998;4:321-7.
5. Ernstoff MCC, Urba W, Flaherty L, et al. A Cytokine Working Group (CWG) 3-arm phase II trial of gp100 (209-2M) peptide + high dose (HD) interleukin-2 in HLA-A2+ (A2+) advanced melanoma patients. J Clin Oncol 2005;24:711s.
6. + regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 2006;24:1169-77.
7. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298:850-4.
8. Robertson MJ, Logan T, Blair HM, et al. Phase I study of recombinant human IL-18 (rhIL-18) administered as five daily intravenous infusions every 28 days in patients with solid tumors. J Clin Oncol 2005;24:169S.
9. Atkins MB, Robertson MJ, Gordon M, et al. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res 1997;3:409-17.
10. Leonard JP, Sherman ML, Fisher GL, et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-γ production. Blood 1997;90:2541-8.
11. Gollob JA, Mier JW, Veenstra K, et al. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-γ induction is associated with clinical response. Clin Cancer Res 2000;6:1678-92.
12. Gollob JA, Veenstra KG, Parker RA, et al. Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma. J Clin Oncol 2003;21:2564-73.
13. Atkins MB, Buzaid AC, Houghton AN. Chemotherapy and biochemotherapy. In: Balch C, Houghton A, Jr., Sober A, Soong S, editors. Cutaneous melanoma. 4th ed. St. Louis: Quality Medical Publishing, Inc.; 2003. p. 589-604.
14. McDermott DF, Mier JW, Lawrence DP, et al. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon α-2B in patients with metastatic melanoma. Clin Cancer Res 2000;6:2201-8.
15. Flaherty LE, Atkins M, Sosman J, et al. Outpatient biochemotherapy with interleukin-2 and interferon α-2b in patients with metastatic malignant melanoma: results of two phase II Cytokine Working Group trials. J Clin Oncol 2001;19:3194-202.
16. Keilholz U, Goey SH, Punt CJ, et al. Interferon α-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol 1997;15:2579-88.
17. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and Interferon α-2b. J Clin Oncol 1999;17:968-75.
18. Eton O, Legha SS, Bedikian AY, et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 2002;20:2045-52.
19. Atkins MB, Lee S, Flaherty LE, Sosman JA, Sondak VK, Kirkwood JM. A prospective randomized phase III trial of concurrent biochemotherapy (BCT) with cis-platin, vinblastine, dacarbazine (CVD), IL-2 and interferon α-2b (IFN) versus CVD alone in patients with metastatic melanoma (E3695): an ECOG-coordinated intergroup trial. In: Program and abstracts of the American Society of Clinical Oncology Annual Meeting; May 31-June 3, 2003: Chicago, IL. pp. 708a.
20. Atkins MB, Gollob JA, Sosman JA, et al. W. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-α 2B in patients with metastatic melanoma. Clin Cancer Res 2002;8:3075-81.
21. O'Day SJ, Boasberg PD, Piro L, et al. Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy. Clin Cancer Res 2002;8:2775-81.
22. O'Day S, Weber J, Thompson J, et al. A Phase II multi-center Trial of maintenance biotherapy (MBT) after induction concurrent biochemotherapy (BCT) for patients (pts) with metastatic melanoma. J Clin Oncol 2005;24:7510s.
23. Phan GQ, Attia P, Steinberg SM, White DE, Rosenberg SA. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 2001;19:3477-82.
24. Atkins MB, Shet A, Sosman JA. IL-2 clinical applications: melanoma. In: DeVita VT, Jr., Hellman S, Rosenberg SA, editors. Biologic therapy of cancer principles and practice. 3rd ed. Philadelphia: JB Lippincott Company; 2000. p. 50-73.
25. Gogas H, Ioannovich J, Dafni U, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006;354:709-18.
26. Ribas A, Camacho LH, Lopez-Berenstein G, et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675, 206. J Clin Oncol 2005;23:8968-77.
27. Wang E, Miller LD, Ohnmacht GA, et al. Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res 2002;62:3581-6.
28. Mori T, Umentani N, Kuo C, et al. Circulating methylated DNA in serum predicts melanoma patients' response to biochemotherapy. J Clin Oncol 2005;24:715s.